Library / Blends / Retatrutide + Cagrilintide
Triple incretin + amylin shop blend
Retatrutide + Cagrilintide
Blend
ClassVendor metabolic pair
Typical routes in papersUsually separate schedules in serious use
Half-life contextWeekly-class agents
EvidenceEach has trials; the co-lyophilized vial does not
What it is
Some catalogs freeze-dry retatrutide with cagrilintide. That is a shop stack: a triple GLP-1/GIP/glucagon agonist plus an amylin analog. There is no approved combo product.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- What people want: maximum appetite-and-fuel lever in one box.
- Titration of two GI-heavy agents at a locked ratio is the practical problem.
- Read the solo Retatrutide and Cagrilintide pages.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Retatrutide: GLP-1 + GIP + glucagon. Cagrilintide: amylin. Overlapping satiety, extra nausea risk.
Possible side effects / caveats
GI load, pulse/glucagon effects from reta, amylin-slowed stomach. Not a beginner mix.
Protocol ranges
| Source tier | Amount | Frequency / duration | Notes |
|---|---|---|---|
| Vendor vials | Milligram splits vary | Do not copy a trial of either drug into a mix | COA first |
| See also | Retatrutide, Cagrilintide, CagriSema | Related |
Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.